GLPG0974   Click here for help

GtoPdb Ligand ID: 8417

Synonyms: compound 99 [PMID 25380412]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: GLPG0974 was a lead clinical development candidate. It acts as an antagonist of the free fatty acid receptor 2 (FFA2) [3]. FFA2 is a GPCR involved in the mediation of inflammatory responses.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 10
Topological polar surface area 106.16
Molecular weight 484.12
XLogP 4.17
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC(=O)CCCN(C(=O)C1(C)CCN1C(=O)c1csc2c1cccc2)Cc1cccc(c1)Cl
Isomeric SMILES OC(=O)CCCN(C(=O)[C@@]1(C)CCN1C(=O)c1csc2c1cccc2)Cc1cccc(c1)Cl
InChI InChI=1S/C25H25ClN2O4S/c1-25(11-13-28(25)23(31)20-16-33-21-9-3-2-8-19(20)21)24(32)27(12-5-10-22(29)30)15-17-6-4-7-18(26)14-17/h2-4,6-9,14,16H,5,10-13,15H2,1H3,(H,29,30)/t25-/m1/s1
InChI Key MPMKMQHJHDHPBE-RUZDIDTESA-N
No information available.
Summary of Clinical Use Click here for help
A Phase 2 clinical trial evaluating GLPG0974 in ulcerative colitis has been completed (NCT01829321). Safety, pharmacokinetics and pharmacodynamics of GLPG0974 in healthy subjects are reported in [2]. However, despite mediating an inhibition of neutrophil influx, GLPG0974 failed to reach the study endpoint in ptients with ulcerative colitis.